Cytonome provides tech support to world’s first commercial iPSC facility

In News by

Sumitomo Dainippon Pharma has installed Cytonome’s cell sorting platform, GigaSort® technology in its newly opened regenerative medicine and cell therapy manufacturing plant in Osaka, Japan.

Cytonome is a biotechnology instrument design company focused on developing cell purification technologies for the bioprocessing, industrial and life science research markets. Its GigaSort platform is a microfluidic-based cell sorting technology that allows the selection of specific and pure cell populations in a cGMP manufacturing environment. The highly parallel microfluidic channel design allows high throughput processing that remains gentle on the cells. The microfluidic chip is part of a disposable, enclosed fluidic set that can be gamma irradiated, eliminating the need for aerosol containment.

Headquartered in Osaka, Japan, Sumitamo Dainippon’s newly opened plant is the world’s first facility for the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells. Sumitomo Dainippon Pharma is currently engaged in the regenerative medicine and cell therapy business using allogeneic iPS cells for the treatment of various diseases including age-related macular degeneration, Parkinson’s disease, retinitis pigmentosa and spinal cord injury.

Dr John Sharpe, Cytonome’s CTO commented: “We are thrilled to be providing the GigaSort technology to Sumitomo Dainippon Pharma Co., Ltd. to enable exciting advances in regenerative medicine and the transition from proof of concept into accessible, manufacturable products.”

Source: Sumitomo Dainippon Pharma Co., Ltd. Chooses Cytonome’s GigaSort® Cell Sorting Technology for Cell Bioprocessing; Press Release